Follow Us

The Latest

Promo Image

Access to Efavirenz and Amprenavir

As reported in last month's TI, efavirenz (Sustiva), the newly approved nonnucleoside analog from DuPont, is embroiled in a dispute over its exceptionally high price. DuPont's negotiations with various state AIDS Drug Assistance Programs over efavire...

Promo Image

FDA Approves New Drug to Treat HIV, AIDS

The Food and Drug Administration has approved efavirenz, a new drug, to treat HIV and AIDS in children and adults. Efavirenz, in combination with other antiretroviral agents, was approved to treat HIV-1 infection after 24-week studies showed it to be...

Promo Image

What Price Efavirenz?

DuPont Pharmaceutical's new drug efavirenz (Sustiva) has enjoyed a favored position among treatment activists, offering both high levels of antiviral activity and a simplified dosing regimen. The company has worked to build a harmonious relationship ...

Promo Image

More on Efavirenz

Efavirenz (SUSTIVA, formerly known and still thought of as DMP-266) received a lot of attention. See the DMP266-006 study for an important head to head comparison of AZT/3TC efavirenz, AZT/3TC indinavir vs. efavirenz indinavir. One of the limitations...

Promo Image

Efavirenz Pregnancy Warning

The Division of AIDS Services (DAIDS) has issued a pregnancy safety alert to its trial sites regarding efavirenz (also known as DMP 266 and Sustiva) based on information provided by the drug's manufacturer, DuPont Merck. A study conducted by the comp...

Promo Image

DMP 266 Now Available

DuPont Merck's potent new non-nucleoside reverse transcriptase inhibitor DMP 266, now called Sustiva or efavirenz, will be made available in October through a limited expanded access program. To be eligible for the program, individuals must have had ...